AMPH

#2482
Amphastar Pharmaceuticals, Inc.
21.4100 USD
+0.14%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
21.3750
21.4300
Intervallo Annuale
17.0300
29.5200
Variazione giornaliera
+0.14%
Variazione Mensile
+13.10%
Variazione di 6 mesi
-12.18%
Variazione Annuale
-12.18%
Chiusura Precedente
21.3800
Apertura
21.3750
Bid
Ask
Minimo
21.3750
High
21.4300
Volume
32
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 971.3754 M
  • Employee 1 976
  • Founded 1996
  • CEO N/A
  • Website www.amphastar.com
  • Headquarter California, United States
  • FIGI BBG000BW90S6
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
13.19
Rapporto prezzo/fatturato
1.79

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

Notizie